Cognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targets

Behavioural Brain Research

Volumn 195, Issue 1, 2008, Pages 30-38

  Terry Jr , Alvin V ^a   Buccafusco, Jerry J ^a   Wilson, Christina ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Alzheimer's disease; Cognition; Dementia; Memory; Schizophrenia; Serotonin

Indexed keywords

RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN RECEPTOR;

ALZHEIMER DISEASE; COGNITIVE DEFECT; HUMAN; MEMORY; MOLECULAR BIOLOGY; NEUROPSYCHIATRY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; ANIMALS; COGNITION; COGNITION DISORDERS; HUMANS; MEMORY; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN AGENTS;

EID: 53149107135     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2007.12.006     Document Type: Review

References (101)

1. Adler L.E., Cawthra E.M., Donovan K.A., Harris J.G., Nagamoto H.T., Olincy A., et al. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry 162 (2005) 386-388
2. Aghajanian G.K., and Merek G.J. Serotonin and hallucinogens. Neuropsychopharmacology 21 2 Suppl. (1999) 16S-23S
3. Aghajanian G.K., and Merek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 31 (2000) 302-312
4. Altman H.J., and Normile H.J. Different temporal effects of serotonergic antagonists on passive avoidance retention. Pharmacol Biochem Behav 28 (1987) 353-359
5. Araneda R., and Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40 (1991) 399-412
6. Barnes J.M., Barnes N.M., Costall B., Naylor R.J., and Tyers M.B. 5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature 338 6218 (1989) 762-763
7. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
8. Bartoszyk G.D., Van Amsterdam C., Bottcher H., and Seyfried C.A. EMD 281014, a new selective serotonin 5-HT2A receptor antagonist. Eur J Pharmacol 473 (2003) 229-230
9. Bass E.W., Means L.W., and McMillen B.A. Buspirone impairs performance of a three-choice working memory water escape task in rats. Brain Res Bull 28 (1992) 455-461
10. Bertrand F., Lehmann O., Galani R., Lazarus C., Jeltsch H., and Cassel J.C. Effects of MDL 73005 on water-maze performances and locomotor activity in scopolamine-treated rats. Pharmacol Biochem Behav 68 (2001) 647-660
11. Bickmeyer U., Heine M., Manzke T., and Richter D.W. Differential modulation of I(h) by 5-HT receptors in mouse CA1 hippocampal neurons. Eur J Neurosci 16 (2002) 209-218
12. Bliss T.V., and Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361 (1993) 31-39
13. Bös M., Sleight A.J., Godel T., Martin J.R., Riemer C., and Stadler H. 5-HT(6) receptor antagonists: lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides. Eur J Med Chem 36 (2001) 165-178
14. Bowen D.M., Francis P.T., Chessell I.P., and Webster M.T. Neurotransmission--the link integrating Alzheimer research?. Trends Neurosci 17 (1994) 149-150
15. Buhot M.C., Martin S., and Segu L. Role of serotonin in memory impairment. Ann Med 32 (2000) 210-221
16. Buhot M.C., and Naili S. Changes in exploratory activity following stimulation of hippocampal 5-HT1A and 5-HT1B receptors in the rat. Hippocampus 5 (1995) 198-208
17. Buhot M.C., Patra S.K., and Naili S. Spatial memory deficits following stimulation of hippocampal 5-HT1B receptors in the rat. Eur J Pharmacol 285 (1995) 221-228
18. Carey G.J., Costall B., Domeney A.M., Gerrard P.A., Jones D.N., Naylor R.J., and Tyers M.B. Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset. Pharmacol Biochem Behav 42 1 (1992) 75-83
19. Carli M., and Samanin R. 8-Hydroxy-2-(di-n-propylamino) tetralin impairs spatial learning in a water maze: role of post-synaptic 5-HT1A receptors. Br J Pharmacol 105 (1992) 720-726
20. Carlsson M.L., Martin P., Nilsson M., Sorensen S.M., Carlsson A., Waters S., et al. The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. J Neural Transm 106 (1999) 123-129
21. Cho S., and Hu Y. Activation of 5-HT4 receptors inhibits secretion of β-amyloid peptides and increases neuronal survival. Exp Neurol 203 (2007) 274-278
22. Chugh Y., Saha N., Sankaranarayanan A., and Datta H. Enhancement of memory retrieval and attenuation of scopolamine-induced amnesia following administration of 5-HT3 antagonist ICS 205-930. Pharmacol Toxicol 69 (1991) 105-106
23. Chugh Y., Saha N., Sankaranarayanan A., and Sharma P. Memory enhancing effects of granisetron (BRL 43694) in a passive avoidance task. Eur J Pharmacol 203 (1991) 121-123
24. Cross A.J., Slater P., Perry E., and Perry R.H. An autoradiographic analysis of serotonin receptors in human temporal cortex: changes in Alzheimer-type dementia. Neurochem Int 13 (1988) 89-96
25. Dawson L.A., and Nguyen H.Q. Li P. The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25 (2001) 662-668
26. Dawson L.A., Nguyen H.Q., and Li P. Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT(6) receptor antagonist. Brain Res Bull 59 (2003) 513-521
27. Dijk S.N., Francis P.T., Stratmann G.C., and Bowen D.M. NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist. Br J Pharmacol 115 (1995) 1169-1174
28. Eglen R.M., Wong E.H.F., Dumuis A., and Bockaert J. Central 5-HT4 receptors. Trends Pharmacol Sci 16 (1995) 391-398
29. Eglen R.M. 5-Hydroxytryptamine (5-HT4) receptors and central nervous system function: an update. In: Jucker E. (Ed). Progress in Drug Research vol. 49 (1997), Burkhäuser Verlag, Basel, Switzerland 9-21
30. Ellis K.A., and Nathan P.J. The pharmacology of human working memory. Int J Neuropsychopharmacol 4 (2001) 299-313
31. Foley A.G., Murphy K.J., Hirst W.D., Gallagher H.C., Hagan J.J., Upton N., et al. The 5-HT6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 29 (2004) 93100
32. Fontana D.J., Daniels S.E., Henderson C., Eglen R.M., and Wong E.H.F. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology 120 (1995) 409-417
33. In: Fozard J.R. (Ed). The peripheral actions of 5-hydroxytryptamine (1989), Oxford University Press, New York
34. Frantz K.J., Hansson K.J., Stouffer D.G., and Parsons L.H. 5-HT6 receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine. Neuropharmacology 42 (2002) 170-180
35. Geyer M.A. Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiatry 31 Suppl 2 (1998) 73-79
36. Gray J.A., and Roth B.L. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12 (2007) 904-922
37. Gurevich E.V., and Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42 (1997) 529-545
38. Harder J.A., Maclean C.J., Alder J.T., Francis P.T., and Ridley R.M. The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. Psychopharmacology (Berl) 127 (1996) 245-254
39. Harder J.A., and Ridley R.M. The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology 39 (2000) 547-552
40. Harrell A.V., and Allan A.M. Improvements in hippocampal-dependent learning and decremental attention in 5-HT(3) receptor overexpressing mice. Learn Mem 10 (2003) 410-419
41. Hirst W.D., Stean T.O., Rogers D.C., Sunter D., Pugh P., Moss S.F., et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 553 (2006) 109-119
42. Hong E., and Meneses A. Systemic injection of p-chloroamphetamine eliminates the effect of the 5-HT3 compounds on learning. Pharmacol Biochem Behav 53 (1996) 765-769
43. Hoyer D., Hannona J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71 (2002) 533-554
44. Iidaka T., Ozaki N., Matsumoto A., Nogawa J., Kinoshita Y., Suzuki T., et al. A variant C178T in the regulatory region of the serotonin receptor gene HTR3A modulates neural activation in the human amygdala. J Neurosci 25 (2005) 6460-6466
45. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100, 907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277 (1996) 968-981
46. Kia H.K., Brisorgueil M.J., Daval G., Langlois X., Hamon M., and Verge D. Serotonin1A receptors are expressed by a subpopulation of cholinergic neurons in the rat medial septum and diagonal band of broca-a double immunocytochemical study. Neuroscience 75 (1996) 143-154
47. Kilpatrick G.J., Jones B.J., and Tyers M.B. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330 (1987) 746-768
48. King M.V., Sleight A.J., Woolley M.L., Topham I.A., Marsden C.A., and Fone K.C. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation--an effect sensitive to NMDA receptor antagonism. Neuropharmacology 47 (2004) 195-204
49. Koike K., Hashimoto K., Takai N., Shimizu E., Komatsu N., Watanabe H., et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophrenia Res 76 (2005) 67-72
50. Lacroix L.P., Dawson L.A., Hagan J.J., and Heidbreder C.A. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 51 (2004) 158-164
51. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44 (1998) 151-162
52. Madjid N., Tottie E.E.l., Luttgen M., Meister B., Sandin J., Kuzmin A., Stiedl O., and Ogren S.O. 5-hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. J Pharmacol Exp Ther 316 (2005) 581-591
53. Manuel-Apolinar L., and Meneses A. 8-OH-DPAT facilitated memory consolidation and increased hippocampal and cortical cAMP production. Behav Brain Res 148 (2004) 179-184
54. Marcinkiewicz M., Verge D., Gozlan H., Pichat L., and Hamon M. Autoradiographic evidence for the heterogeneity of 5-HT1 sites in the rat brain. Brain Res 291 (1984) 159-163
55. Matsukawa M., Ogawa M., Nakadate K., Maeshima T., Ichitani Y., Kawai N., et al. Acetylcholine are cucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci Lett 230 (1997) 13-16
56. Maura G., Andrioli G.C., Cavazzani P., and Raiteri M. 5-Hydroxytryptamine3 receptors sited on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release. J Neurochem 58 6 (1992) 2334-2337
57. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 2 Suppl. (1999) 106S-115S
58. Mendelson S.D., Quartermain D., Francisco T., and Shemer A. 5-HT1A receptor agonists induce anterograde amnesia in mice through a postsynaptic mechanism. Eur J Pharmacol 236 (1993) 177-182
59. Meneses A. 5-HT system and cognition. Neurosci Biobehav Rev 23 (1999) 1111-1125
60. Meneses A. Role of 5-HT6 receptors in memory formation. Drug News Perspect 14 (2001) 396
61. Meneses A., and Perez-Garcia G. 5-HT1A receptors and memory. Neurosci Biobehav Rev 31 (2007) 705-727
62. Middlemiss D.N., Palmer A.M., Edel N., and Bowen D.M. Binding of the novel serotonin agonist 8-hydroxy-2-(di-n-propylamino)tetralin in normal and Alzheimer brain. J Neurochem 46 (1986) 993-996
63. Misane I., and Ogren S.O. Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology 28 (2003) 253-264
64. Mohler E., Shacham S., Noiman S., Lezoualc'h F., Robert S., Gastineau M., et al. VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacology 53 (2007) 563-573
65. Moser P.C., Bergis O.E., Jegham S., Lochead A., Duconseille E., Terranova J.P., et al. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther 302 (2002) 731-741
66. Ngan E.T., Yatham L.N., Ruth T.J., and Liddle P.F. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone. Am J Psychiatry 157 (2000) 1016-1018
67. Niesler B., Flohr T., Nöthen M.M., Fischer C., Rietschel M., Franzek E., et al. Association between the 5′ UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics 11 (2001) 471-475
68. Offord SJ. M100907, a highly selective 5-HT2A antagonist for treatment of schizophrenia: early indication of safety and clinical activity in schizophrenic patients (Abstr.), in XXIst Collegium Internationale Neuro-Psychopharmacologicum Congress, Glasgow, PT10052. Cambridge University Press.
69. The rat nervous system. In: Paxinos G. (Ed). Forebrain and midbrain vol. 1 (1985), Academic Press, San Diego
70. Perez-Garci{dotless}a G.S., and Meneses A. Effects of the potential 5-HT7 receptor agonist AS 19 in an autoshaping learning task. Behav Brain Res 163 (2005) 136-140
71. Pitsikas N., Brambilla A., and Borsin F. Effect of DAU 6215, a novel 5-HT3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task. Pharmacol Biochem Behav 47 (1994) 95-99
72. Pouzet B., Didriksen M., and Arnt J. Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol Biochem Behav 71 (2002) 655-665
73. Rapport M.M., Green A.A., and Page I.H. Serum vasoconstrictor (serotonin) isolation and characterization. J Biol Chem 176 (1948) 1243-1251
74. Riad M., Emerit M.B., and Hamon M. Neurotrophic effects of ipsapirone and other 5-HT1A receptor agonists on septal cholinergic neurons in culture. Dev Brain Res 82 (1994) 245-258
75. Riemer C., Borroni E., Levet-Trafit B., Martin J.R., Poli S., Porter R.H., et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem 46 (2003) 1273-1276
76. Roberts A.J., Krucker T., Levy C.L., Slanina K.A., Sutcliffe J.G., and Hedlund P.B. Mice lacking 5-HT receptors show specific impairments in contextual learning. Eur J Neurosci 19 (2004) 1913-1922
77. Rogers D., and Hagan J. 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology 158 (2001) 114-119
78. Roth B.L., Hanizavareh S.M., and Blum A.E. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 174 (2004) 17-24
79. Scatton B., and Sander D.J. Pharmacological and molecular targets in the search for novel antipsychotics. Behav Pharmacol 11 (2000) 243-256
80. Schechter L.E., Smith D.L., Rosenzweig-Lipson S., Sukoff S.J., Dawson L.A., Marquis K., et al. (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther 314 (2005) 1274-1289
81. Schechter LE, Lin Q, Smith DL, Zhang G, Shan Q, Platt B, Brandt MR, Dawson LA, Cole D, Bernotas R, Robichaud A, Rosenzweig-Lipson S, Beyer CE. Neuropharmacological profile of novel and selective 5-HT(6) receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 2007, in press, doi:10.1038/sj.npp.1301503.
82. Sipes T.E., and Geyer M.A. DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Brain Res 761 (1997) 97-104
83. Stean T.O., Hirst W.D., Thomas D.R., Price G.W., Rogers D., Riley G., et al. Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist. Pharmacol Biochem Behav 71 (2002) 645-654
84. Terry Jr. A.V. Drugs that target serotonergic receptors. In: Buccafusco J.J. (Ed). Cognitive Enhancing Drugs (2004), Birkhauser Verlag, Basel, Switzerland 79-88
85. Terry Jr. A.V., Buccafusco J.J., Jackson W.J., Prendergast M.A., Fontana D.J., Wong E.H., et al. Enhanced delayed matching performance in younger and older macaques administered the 5-HT4 receptor agonist, RS-17017. Psychopharmacology 135 (1998) 407-415
86. Terry Jr. A.V., Buccafusco J.J., Prendergast M.A., Jackson W.J., Fontana D.L., Wong E.H.F., et al. The 5-HT3 receptor antagonist, RS-56812, enhances delayed matching performance in monkeys. NeuroReport 8 (1996) 49-54
87. Terry Jr. A.V., Buccafusco J.J., and Bartoszyk G.D. Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. Psychopharmacology (Berl) 179 (2005) 725-732
88. Thompson A.J., and Lummis S.C. The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets 11 (2007) 527-540
89. Tokarski K., Zahorodna A., Bobula B., and Hess G. 5-HT7 receptors increase the excitability of rat hippocampal CA1 pyramidal neurons. Brain Res 993 (2003) 230-234
90. Twarog B.M., and Page I.H. Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol 175 1 (1953) 157-161
91. Van den Hooff P., and Galvan M. Electrophysiology of the 5-HT1A ligand MDL 73005EF in the rat hippocampal slice. Eur J Pharmacol 196 (1991) 291-298
92. Van den Hooff P., and Galvan M. Actions of 5-hydroxytryptamine and 5-HT1A receptor ligands on rat dorso-lateral septal neurons in vitro. Br J Pharmacol 106 (1992) 893-899
93. Varty G.B., Bakshi V.P., and Geyer M.A. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20 (1999) 311-321
94. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Babler A., Vogel H., and Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9 (1998) 3897-3902
95. Waeber C., Hoyer D., and Palacios J.M. 5-Hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]CS 205030. Neuroscience 31 (1989) 393-400
96. Williams G.V., Rao S.G., and Goldman-Rakic P.S. The physiological role of 5-HT2A receptors in working memory. J Neurosci 22 (2002) 2843-2854
97. Williams J., Spurlock G., McGuffin P., Mallet J., Nöthen M.M., Gill M., et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 347 (1996) 1294-1296
98. Winstanley C.A., Chudasama Y., Dalley J.W., Theobald D.E., Glennon J.C., and Robbins T.W. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology (Berl) 167 (2003) 304-314
99. Woolley M.L., Bentley J.C., Sleight A.J., Marsden C.A., and Fone K.C. A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 41 (2001) 210-219
100. Woolley M.L., Marsden C.A., Sleight A.J., and Fone K.C. Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. Psychopharmacology (Berl) 170 (2003) 358-367
101. Xia Z., Gray J.A., Compton-Toth B.A., and Roth B.L. A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J Biol Chem 278 (2003) 21901-21908